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Abstract
Pediatric lung transplantation has advanced over the years, providing a potential life-
prolonging therapy topatientswith cystic fibrosis.Despite this,many challenges in lung
transplantation remain and result in worse outcomes than other solid organ
transplants. As CF lung disease progresses, children and their caregivers are often
simultaneously preparing for lung transplantation and end of life. In this article, we will
discuss the current barriers to success in pediatric CF lung transplantation as well as
approaches to end of life care in this population.
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1 | LUNG TRANSPLANTATION
Pediatric lung transplantation offers treatment to thosewith end-stage
cystic fibrosis (CF) lung disease. While survival has improved since the
first lung transplant was performed in 1987, the median survival
remains lower than other solid organ transplants at 4.9 years.1 Many
issues result in this somewhat stagnant median survival and include
patient selection, center experience, lung allocation strategies, and
slow advances in immunosuppressant therapy.
1.1 | Chronicity of disease and psychosocial impact
Potential pediatric lung transplant candidates are referred to
transplant centers with a variety of underlying diagnoses, including
chronic lifelong diseases such as CF and other conditions that can
present later in childhood such as idiopathic pulmonary arterial
hypertension, idiopathic pulmonary fibrosis, bronchiolitis obliterans,
and pulmonary fibrosis.1 Variations in disease chronicitymay affect the
attitudes, behaviors and outcomes of children and adolescents
undergoing lung transplantation. While one might predict worse
outcomes in those with chronic diseases, adult studies have actually
shown greater improvement in a number of quality of life measures in
patients with CF when compared to those with other diagnoses.2
The chronic nature of their disease does result in patients with CF
presenting for lung transplantation accompanied by numerous
comorbidities, both physical and psychosocial. These may include
severe infectious complications with multidrug resistant organisms,
history of prior chest surgeries, need for invasive mechanical
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ventilation, pulmonary hypertension, cardiac dysfunction, liver
disease, nutritional failure, diabetes mellitus, depression/anxiety,
osteoporosis, gastroesophageal reflux, and others.3 It is essential to
acknowledge that the treatment burden for patients with CF is
extraordinary, often requiring 2-3 h each day for routine CF care with
significantly increased treatment times for those with end-stage
disease.4While this large treatment burdenmay allow patientswith CF
to be more prepared for the chronic treatments required after
transplant, it can also lead to significant emotional strain while waiting
on the transplant list. As severe end stage lung disease and death
among children with CF is relatively uncommon in comparison to
adults, there may be delays in referral for lung transplantation and/or
delayed conversations about palliative care and end of life.5
Comorbidities, both physical and emotional, often add to the
complexity of post-transplant care.6
Numerous studies have assessed the pre-transplant quality of life
in patients with CF and demonstrated significant social challenges of
living with CF as well as social isolation from CF peers.7 Patients with
severe CF lung disease have high levels of psychosocial distress and
less commonly attend school or work,8 however, a study by Burker
et al revealed that patients with CF awaiting lung transplantation may
actually be more functional than their non-CF peers awaiting the same
surgery. While the CF patients in this study appeared sicker than their
non-CF peers, the fact that they have been managing their disease
their whole lives may have made themmore adaptable as their disease
progressed. All of these factors, whether provocative or protective,
may be upended as the CF patient is ultimately listed for lung
transplantation and experiences ongoing decline in their health,
potential geographic relocation close to the transplant center and fears
that they might not survive to achieve the goal of transplant.9
1.2 | Outcomes
Pediatric lung transplantation has spanned three decades with over
2200 lung transplants reported in0-18yearolds todate.10Pediatric lung
transplants have been performed in over 40-50 centers worldwide.
Since the early 1990’s there has been an increase in both the number of
patients receiving lung transplants and post-transplant survival.
Reported pediatric lung transplants per year now ranges from roughly
100-137 per year worldwide. The majority of pediatric lung transplants
are performed in 11-17 year-olds andCF is themost common indication
for transplant. Therehas beenamodest improvement inmedian survival
when comparing cohorts before and after the year 2000 (3.3 vs 5.8
years, P = 0.0007), but certainly survival lags behind most other solid
organ transplants.10 There is no significant difference in post-transplant
median survival based on underlying indication for lung transplant.
(Fig. 1) The ISHLT registry compared patients with CF, interstitial lung
disease, and all forms of pulmonary hypertension with no significant
survival difference between these cohorts. Survival in pediatrics is
generally comparable to adults although there are some subtle
differences. Adults receiving bilateral lung transplants, excluding single
lung transplant recipients representing roughly 25% of all adult lung
transplants, have a greater median survival than pediatric patients
receiving bilateral lung transplants.10 A more recent assessment of
survival of adolescent transplant recipients, which defined adolescent
patients from 10 to 24 years of age, found that adolescents had poorer
overall survival when compared to younger children and adults. Most
importantly, the 15-19 years old age group had the worst outcomes.
AdolescentswithCFhadbetter 1 and3-year survivalwhencompared to
non-CFpatients.11Assessment of psychosocial concerns for adolescent
lung transplant recipients revealed that this agegroupoftenexperiences
depression, anxiety, school phobia, and post-traumatic stress syn-
drome.12 Adolescent recipients’ expectations of transplant play a
significant role, with difficulty adjusting to unmet goals.13 Interestingly
as well, gender trends reveal a survival advantage to male compared to
female recipients in pediatrics; a trend that is not noted in the adult lung
transplant cohort.10,14
Center volume and center type both have an impact on survival.
While children transplanted at larger volume pediatric centers have
improved survival compared to those transplanted at smaller volume
centers, this survival advantage did not carry over to children
transplanted at large volume adult centers, suggesting that pediatric
expertise also plays an important role in survival.15 CF-specific
experience is also important: Hayes et al16 found that CF lung
transplant volume was a stronger predictor of overall survival than
overall transplant volume alone.
Lung allocation scoring (LAS) was implemented in 2005 with the
intention of decreasing pre-transplant mortality and increasing post-
transplant survival. Since this time there has been a significant
improvement in wait list mortality in all age groups, with decreased
wait times.17 Children continue to have an increased waitlist mortality
compared with adults.18 Ongoing refinement of the LAS is needed to
improve survival for all patients waiting.18,19
Survival post lung transplant reveals variation by age, with 6-10
year-old recipients demonstrating a survival advantagewhen compared
to 11-17 year-old recipients (8.2 vs 4.8 years, P < 0.5). Recipients under
6 years of age demonstrate a non-statistical increase in median survival
when compared to 11-17 year-olds. Bronchiolitis obliterans and graft
failure continue to be the major causes of death in all age groups.10
FIGURE 1 Kaplan Meier plot of conditional one year survival
for pediatric lung transplantation. Permission “Presented by Josef
Stehlik, MD, MPH on behalf of ISHLT International Thoracic
Transplant Registry Steering Committee at ISHLT 2017 37th
Annual Meeting & Scientific Session, San Diego, CA”
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1.3 | Areas in need of exploration and developing
therapies
With a lack of considerable improvements in clinical outcomes, the
potential for significant advances in pediatric lung transplantation exists.
As stated above, the challenges andoutcomes in lung transplantation are
similar for all patients, including those with CF. To start, universally
accepteddiagnosticcriteria forpost-transplantcomplicationsare limited;
this is being addressed by the International Society for Heart and Lung
Transplantation (ISHLT). Therapies topreventand treatgraft rejection, to
bridge patients to transplant, and to increase the donor organ pool all
warrant ongoing investigation. For patients with CF, it will be these new
therapies that will unlock the potential for increased survival.
The most recent published consensus statement by the ISHLT
focused on antibody-mediated rejection (AMR), including consider-
ations for pediatric recipients.20 AMR is now widely recognized as a
cause of allograft dysfunction in lung transplant recipients, but neither
diagnostic criteria nor treatment strategies are fully established nor
universally accepted. Bortezomib, an inhibitor of the 26S proteosome
that depletes plasma cells, and eculizimab, a complement-inhibitory
monoclonal antibody that inhibits assembly of the membrane attack
complex via C5, are newer therapies that are being introduced by
clinicians.21–23 In a recent study using a proteasome inhibitor-based
therapy with carfilzomib for AMR, responders of the treatment
regimen had less chronic lung allograft dysfunction or progression.24
Further study is required before their administration can be
recommended in pediatric lung transplant recipients.
Contemporary maintenance immunosuppressive regimens for lung
transplantation include a calcineurin inhibitor, an antiproliferative agent
and a corticosteroid, but the toxicity of calcineurin inhibitors and
corticosteroids are significant, with little improvement in outcomes. As
previously noted, CF patients generally arrive for lung transplantation
already with substantial toxicities, including renal disease from chronic
antibiotic exposure. Advances in the calcineurin inhibitor class areunder
development with voclosporin, a cyclosporine analog. Voclosporin has
been delivered safely to renal transplant recipients, appears to be as
efficacious as tacrolimus in preventing acute rejection, and may be
associated with a reduced incidence of new onset diabetes after
transplantation.25,26 A potential replacement for calcineurin inhibitors,
belatacept, a selective T-cell costimulation blocker comprised of a
recombinant extracellular domain of human cytotoxic T lymphocyte
antigen-4 (CTLA-4) and a fragment of a modified Fc portion of human
IgG1, is also under study. Belatacept binds to CD 80/86 ligands of
antigen-stimulating cells and thereby inhibits CD-28-mediated T-cell
co-stimulationwith recent evidence showing significantly higher patient
and graft survival and mean eGFR with renal transplant recipients
receiving belatacept than cyclosporine seven year after transplanta-
tion.27 Additionally, phase 2 trials minimizing and avoiding calcineurin
inhibitor regimens is underway in renal transplantation using the novel
anti-CD40 monoclonal antibody, ASKP1240.28,29
For chronic lung allograft dysfunction including bronchiolitis
obliterans syndrome (BOS), extracorporeal photopheresis (ECP) is
associated with a reduction in the levels of circulating donor specific
antibodies, antibodies to lung-associated self-antigens (Kα1T, collagen
I, and collagen V), and circulating levels of pro-inflammatory cytokines
which may injure the transplanted lung.30 Although ECP has been
reported in a pediatric lung transplant recipient,31 there are no formal
studies addressing its use in children with BOS. Recently, the infusion
of allogeneic bonemarrow-derivedmesenchymal stem cells was found
to be feasible and safe in lung transplant recipients with BOS. A Phase
2 randomized controlled trial to assess the efficacy of this cell therapy
will be conducted by the Australian Lung Transplant Collaborative.32
With a need to expand donor lung allocation, ex vivo lung
perfusion was developed to rehabilitate organs not acceptable for
transplantation based on accepted standards,33,34 Although ex vivo
lung perfusion has been successfully used in children at The Hospital
for Sick Children in Toronto (SolomonM, personal communication) its
application in pediatric transplant is yet to be determined.
It is important to note that, historically, intubation and mechanical
ventilation for patients with CF has been controversial for patients with
advanced lung disease due to poor outcomes and high mortality even if
on the waitlist for lung transplantation.35,36 With advances in
antimicrobial and mechanical ventilation strategies as well as extracor-
poreal life support, CF patients can successfully be supported to
recovery or bridged to lung transplantation at a few select centers.37–41
In fact, long-term clinical outcomes in children treated with extracorpo-
real membrane oxygenation at the time of lung transplantation were
found to be similar to those who were not,42 and use of mechanical
ventilation at time of lung transplant did not influence survival or
development of bronchiolitis obliterans syndrome in pediatric CF
recipients.43 Patients with CF should not be excluded from the use of
bridging therapies due to their underlying genetic disease.
The development of universally accepted diagnostic approaches
and treatment guidelines will be vital for the standardization of
practice and the advancement of research for pediatric lung transplant
recipients. Although few immunosuppressants and therapies are
currently in clinical trials, the agents and approaches under develop-
ment have shown great promise to potentially significantly impact
outcomes. In order to optimize clinical outcomes after pediatric lung
transplantation, it will be vital to enroll children into these studies.
While great improvements have occurred within pediatric lung
transplantation, survival still remains lower than other solid organ
transplants. Barriers to increasing survival include psychosocial aspects
of care as well as challenges in preventing and treating rejection in this
population. PatientswithCFshare thesepsychosocial burdens aswell as
often bring significant morbidities to their lung transplant. Collaborative
work must be done in pediatric lung transplant patients to continue to
advance our knowledge in these areas.
2 | END OF LIFE CARE
There are clearly great advances and challenges in lung transplantation
as noted above. Importantly, additional advances in CF care have led to
increasing life expectancy such that the majority of individuals living
with CF are now adults. However, whether lung transplantation is
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considered or not, CF remains a life-threatening condition, with most
deaths occurring from complications of lung disease or lung
transplantation.44 As a result, both pediatric and adult CF care providers
must be prepared to address patient preferences for care near the endof
life and tohelpmanageboth thephysical andemotional aspectsof careof
a dying patient. Many CF providers may not feel equipped to do so
without additional training and support.45,46 In order to provide high
quality care throughout the lifespan, including end of life, CF care
providers must help patients and their family caregivers manage
uncertainty, navigate disease progression and choices around manage-
ment of progressive disease, and communicate wishes for end of life
care.47,48Wewill highlight importantaspectsof careofpeopledying from
complicationsofCFandhope topromoteongoingefforts toenhanceend
of life care. It should be noted that this review is limited toendof life care,
and does not encompass all aspects of care of people with advanced
disease or the broader scope of palliative care for people with CF.
Barriers to optimal end of life care for people with CF are
commonly recognized among CF clinicians. While on a population
level, home is the preferred location of care for people dying from
chronic conditions,49 many people with CF die in the hospital, often
in the intensive care unit.50–52 There are likely many reasons for this,
including patient and family comfort with hospital-based care, ever
improving technologies to sustain life,53,54 and the availability of
lung transplantation for select patients, many of whom receive
bridging therapies that are only available in the hospital setting.55
Prognostication can be difficult in CF; lung disease trajectory is
unique to each person with CF (Fig. 2), and not all people dying from
complications of CF have severe lung disease.50,52 The availability of
new therapies like CFTR modulators which hold promise for ever
improving outcomes creates additional challenges to prognostication
and contributes to uncertainty about when and how to communicate
about death and dying. Additionally, the high cost of standard CF
therapies, many of which relieve distressing symptoms, may limit
continuation of these therapies concurrently with hospice care
outside of the hospital.
2.1 | Components of end of life care
As end of life approaches, providers must be prepared to communicate
with patients about their hopes, wishes and goals around death and
dying in a socially and culturally sensitive manner, using language that
is appropriate to the patient’s age, developmental level and health
literacy. Providers should explore with patients where they want to
receive care, which treatments they do and do notwish to receive, how
physical and emotional symptoms will be managed, and they should
provide guidance about what to expect in the dying process. The
National Quality Forum preferred practices, derived from National
Consensus Project Clinical Practice Guidelines for Quality Palliative
Care criteria for care of the imminently dying patient are highlighted in
Table 1.56 These may serve as a framework for CF care providers and
others involved in the care of people dying from CF to ensure that the
needs of patients and family caregivers are addressed. Additional
criteria from other domains of care outlined in this project provide a
more comprehensive framework for quality care for people with
serious illnesses like CF.57
2.2 | Advance care planning
Advance care planning (ACP) is planning for future medical care with
the intent to align treatment choices with individual goals. Products of
ACP may include advance directives such as designation of surrogate
decision makers or documentation of preferences for intensive
interventions like cardiopulmonary resuscitation and intubation, a
comprehensive care plan for symptom management, and legacy
activities. Most people with CF will survive into adulthood, such that
decision- making transfers from surrogates to self, but many adults
with CF will continue to rely on family caregivers for help with
decision-making. It is important to include surrogate decisionmakers in
conversations about treatment preferences and to document patient
wishes so they can be honored by surrogates and health care
providers. While existing literature suggests that ACP is often delayed
or absent fromCF care,50,51,58,59 it appears that there is a trend toward
more ACP.52 Research supports introducing ACP to adolescents with
CF and other serious illnesses,60–63 and tools are available to assist
with both ACP and decision-making.61,64
For those considering or awaiting lung transplantation, decisions
to limit life-sustaining treatments can be particularly complex.
Challenges exist for patients, families and CF providers in simulta-
neously managing end of life care/ACP and maintaining the patient as
an active lung transplant candidate.Often transplant eligibility requires
medication and therapies that may not always be consistent with end
of life practices and this process is challenging for all involved. CF and
transplant care providers are encouraged to engage patients in honest
conversations about implications and anticipated outcomes of treat-
ments like mechanical ventilation and/or ECMO as a bridge to lung
transplantation. Palliative care providers can be helpful for patients,
families and CF providers as they balance these often conflicting
choices.65 Regardless of transplant eligibility or candidacy, preferences
may change as one’s condition changes, and providers should inviteFIGURE 2 Anticipated course of lung disease in cystic fibrosis65
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ongoing conversations about ACP. Additionally, palliative care
consultants, social workers, spiritual care providers, and child life
specialists may be available to partner with patients, family caregivers
and CF care providers in ACP.
2.3 | Symptom management
Distressing symptoms such asdyspnea, cough, pain, fatigue, andanxiety
are common in people dying from complications of CF (Fig. 3).66,67
Achieving effective symptom management necessitates developing an
individualized plan involving pharmacologic and non-pharmacologic
therapies, co-managing discomforts of necessary CF therapies and side
effects of medications used to manage symptoms, and educating
patients and families about symptoms to anticipate as death
approaches. In addition to improving quality of life, effective symptom
management may promote life extension, which is often an important
goal for people with serious illness. General principles of symptom
management at end of life can be applied to the CF population. While
comprehensive review of symptom management and specific recom-
mendations are beyond the scope of this manuscript, we will highlight
some standard practices and also commonmyths that, when allowed to
inform practice, may interfere with optimal care.
TABLE 1 Selected recommendations for end of life care from the National Quality Forum Preferred Practices for end of life care56
Preferred practices at end of life
• Formulate, utilize, and regularly review a timely care plan based on a comprehensive interdisciplinary assessment of the values, preferences, goals
and needs of the patient and family (PP* 6)
• Document the patient/surrogate preferences for goals of care, treatment options, and setting of care at first assessment and at frequent intervals as
conditions change (PP 33).
• Document the designated surrogate decision maker in accordance with state law (PP 32).
• Enable patients to make informed decisions about their care by educating them on the process of their disease, prognosis, and the benefits and
burdens of potential interventions (PP 10).
• For minors with decision-making capacity, document the child’s views and preferences for medical care, including for treatment, and give
appropriate weight in decision-making (PP 38).
• Health care professionals should present hospice as an option to all patients and families when death within a year would not be surprising and
reintroduce the hospice option as the patient declines (PP 8).
• The family is educated on a timely basis regarding signs and symptoms of imminent death in a developmentally, age, and culturally appropriate
manner (PP 27).
• As part of the ongoing care planning process, routinely ascertain and document patient and family wishes about the care setting for site of death
and fulfill patient and family preferences when possible (PP 28).
• Assess and manage symptoms and side effects in a timely, safe, and effective manner to a level acceptable to the patient and family (PP 13).
• Measure and document anxiety, depression, behavioral disturbances, and other common psychological symptoms in a timely, safe, and effective
manner to a level acceptable to the patient and family (PP 15).
• Provide adequate dosage of analgesics and sedatives as appropriate to achieve patient comfort during the active dying phase and address concerns
and fears about using narcotics and of analgesics hastening death (PP 29).
• Recognize and document the transition to the active dying phase and communicate to the patient, family, and staff the expectation of imminent
death (PP 26).
• Assess and manage the psychological reactions of patients and families to address emotional and functional impairment and loss (including stress,
anticipatory grief, and coping) in a regular ongoing fashion (PP 16).
• Develop and offer a grief and bereavement care plan to provide services to patients and families prior to and for at least 13 months after the death
of the patient (PP 17).
*PP, preferred practice.
FIGURE 3 Symptom prevalence and associated distress in the
last week of life as reported by caregivers of children and adults
who died from complications of CF
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As respiratory insufficiency progresses, many people utilize
increasing respiratory support. Oxygen and noninvasive ventilation
are offered to help relieve these symptoms along with standard airway
clearance and aerosolized therapies. Given the complex interplay
between dyspnea, anxiety, and pain, multiple concurrent strategies
such as use of increased respiratory support, modification of airway
clearance therapies, titration of opioids and benzodiazepines, emo-
tional support, and relaxation techniques are often employed. Fears of
opioid side effects such as respiratory depression, altered mental
status, and constipation may limit their use. Access to opioids may be
limited for patients awaiting lung transplant; an informal survey of
transplant physicians revealed concerns about opioids compromising
recovery from transplant and overall success of transplant to the
extent that over half reported only rarely allowing opioid use by
patients awaiting transplant or prohibiting their use entirely.68 Given
the demonstrated efficacy of opioids in relieving dyspnea in a variety of
conditions, adhering to standard practice by starting with very low
doses and titrating to effect, monitoring closely for and proactively
managing any undesirable secondary effects, may reduce worries
around opioid use.66 Concerns about misuse, abuse, and addiction are
often raised; there is no evidence that individuals with CF are more
likely to misuse opioids than healthy peers. In addition, fear of opioids
hastening death should be addressed through responsible dose
titration and acknowledging that changes in respiration and cognition
are manifestations of dying from advanced lung disease.69
Engaging family caregivers in symptommanagement and teaching
them about the signs and symptoms of dying allows them to play an
active role in care and may enhance patient comfort. Effective
treatment of distressing symptoms should allow patients to interact
more easily with loved ones and health care providers at end of life.
Patients with complex symptoms or extreme emotional and/or
physical distress may benefit from consultation with palliative care
providers, pain specialists, mental health providers, and otherswho can
address suffering based on an individual patient’s values, preferences,
beliefs, culture, and religion. Collaborative management is likely to
enhance symptom control and to reduce stress and anxiety for the
patient, family caregivers, and CF care team members.
2.4 | Hospice
Hospice is both an insurance benefit and a philosophy of care that is
desired and appropriate for many people at end of life. While criteria
for hospice eligibility of patients with advanced lung disease exist,47
individual patient factors may dictate appropriate timing of referral,
and utilization of hospice by patients listed for lung transplant may
require careful conversations among CF, transplant and hospice
providers. CF care providers should call on experts to help introduce
hospice care, describing how it can be utilized by people with CF and
their family caregivers, and assistingwith navigation of payment issues.
Negotiating roles of the CF care team when patients elect the hospice
benefit is important; fears of abandonment by long term providers may
affect choices when communication about care plans is unclear.
2.5 | Grief and bereavement care
Improved survival in CF and ongoing advances in therapies affects
attitudes about dying from CF. This, in turn, likely affects acceptance of
death for patients, families, providers, and the CF community at large.
Grief and loss are a part of living with CF from the time of diagnosis, and
bothanticipatory grief and tangible losses increase as disease progresses.
Patients and families should be offered opportunities to assist them in
finding meaning and relieving existential distress, often through
counseling, connections with peers and/or support groups, memory
making, and legacywork that canbe facilitatedbypsychosocial providers.
Ongoing involvementwithbereaved family caregivers following the
death of someone with CF is an option for CF care team members that
maybehelpful toall parties incopingwith loss.ManypeoplewithCFand
their caregivers describe the CF care team as “extended family,” such
thatongoing communication feelsnatural and comforting, particularly in
the weeks to months after death. Psychosocial providers from the CF
care team, hospice, and/orconsulting services canprovidebereavement
care and identify local resources for familymembers and the community
around the dying patient, often including peers with CF.
2.6 | Summary: Lung transplantation and end of life
care
This overview of issues in advanced CF lung disease, including
pediatric lung transplantation and end of life care, is intended to
provide some guidance for CF care providers whowill counsel and care
for patients around lung transplantation and at end of life. As
transplant care and the field of palliative care continue to evolve, there
will be fewer unmet needs of people living with advanced CF lung
disease. Current Cystic Fibrosis Foundation initiatives to develop
clinical practice guidelines for both lung transplant care and palliative
care in CF will help CF care teams and others involved in CF care
provide high quality care at this important stage of life.
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